Bristol-Myers Squibb (NY:BMY)

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 27, 2026

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗

September 27, 2026

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question ↗

Topics Bonds Economy

September 10, 2026

Via Chartmill

Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup ↗

September 05, 2026

Via Chartmill

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

September 25, 2026

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗

Topics Intellectual Property Regulatory Compliance

September 24, 2026

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Topics Intellectual Property

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗

September 20, 2026

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Topics Intellectual Property

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

September 18, 2026

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

September 17, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS...

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Topics Artificial Intelligence Intellectual Property

September 17, 2026

Bristol Myers Squibb Announces Dividend

September 16, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

3 Healthcare Stocks That Fall Short

September 14, 2026

As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.

Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? ↗

September 13, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

Topics Intellectual Property

September 10, 2026

Via Investor Brand Network

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

September 10, 2026

Via Investor Brand Network

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

September 08, 2026

Both have attracted considerable attention from Wall Street recently.

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

From BioMedWire

Via GlobeNewswire

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗

September 03, 2026

The company is coming back into the spotlight thanks to recent developments.

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

September 02, 2026

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

September 02, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest

August 31, 2026

Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return d...

Topics Artificial Intelligence Intellectual Property

3 Reasons to Sell BMY and 1 Stock to Buy Instead

August 31, 2026

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Topics Stocks

August 29, 2026

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Topics Intellectual Property

1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges

August 28, 2026